Reig Jofre + LEO Pharma: Boost for psoriasis treatment…

The pharmaceutical companies Reig Jofre and LEO Pharma have entered into an agreement to provide access to an innovative psoriasis treatment. This agreement aims to enhance the promotion of LEO Pharma’s groundbreaking treatment for mild to moderate psoriasis within the Primary Care sector in Spain. 
 
Psoriasis is one of the most prevalent dermatological conditions, and specialists in Family and Community Medicine play a key role in its diagnosis and management. In the market for topical psoriasis treatments, this drug stands out as the undisputed leader in both Spain and Europe. Supported by guidelines from leading medical societies (SEMFyC, SEMERGEN, and SEMG), it combines calcipotriol, a vitamin D analog, with betamethasone dipropionate. This unique combination significantly improves the antipsoriatic response and has been recognized by Farmaindustria as an incremental innovation, thanks to its advanced foam formulation. Furthermore, it is the only dermatology drug in the national health system to receive this distinction, highlighting its therapeutic relevance and acceptance among dermatology specialists.
 

A journey through the history of the pharmaceutical industry and one of its great laboratories that had its origins in Alfred Nobel...
“From Alfred Nobel to AstraZeneca”: https://a.co/d/9svRTuI